Zoetis Inc. — FY2017 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2017. This is an annual filing, not a standalone fourth-quarter report; quarterly figures below are included where useful. Amounts are U.S. dollars.
Business context
Zoetis discovers, develops, manufactures and sells animal-health medicines and vaccines for livestock and companion animals. It reported through U.S. and International operating segments; contract manufacturing accounted for the remainder of revenue. The U.S. contributed 49% of revenue and International 50%. Livestock represented about 57% of revenue, companion animals 42%, and contract manufacturing 1%.
Key financial metrics
| Metric | FY2017 | FY2016 | Change |
|---|---|---|---|
| Revenue | $5.307 billion | $4.888 billion | +9% reported; +8% operational, with FX adding about 1% |
| Gross profit / gross margin | $3.532 billion / 66.6% | $3.222 billion / 65.9% | Margin improved about 0.7 percentage points |
| Income before tax | $1.525 billion | $1.228 billion | +24% |
| Net income attributable to Zoetis | $864 million | $821 million | +5% |
| Diluted EPS | $1.75 | $1.65 | +6% |
| Adjusted net income (non-GAAP) | $1.185 billion | $975 million | +22% |
| Adjusted diluted EPS (non-GAAP) | $2.40 | $1.96 | +22% |
| Operating cash flow | $1.346 billion | $713 million | +89% |
| Capital expenditures | $224 million | $216 million | +$8 million |
Revenue growth was led by companion animals (+14%), particularly dermatology and new products, including Apoquel, Cytopoint and Simparica. Livestock revenue grew 5%; medicated feed additives declined, in part reflecting U.S. Veterinary Feed Directive effects and product rationalizations. International revenue grew 11% reported and 10% operational; U.S. revenue grew 7%.
Operating cash flow improved with higher earnings, lower employee-termination payments, favorable timing of receipts and payments, and lower inventory. Cash and cash equivalents were $1.564 billion at year-end, versus $727 million. Working capital was $3.123 billion and the current ratio was 3.85:1.
Long-term debt, net of discount and issuance costs, was $4.953 billion, versus $4.468 billion; principal debt outstanding was $5.0 billion. Zoetis issued $1.25 billion of notes in 2017 and used part of the proceeds to repay $750 million of notes due 2018. Interest expense was $175 million, up from $166 million. The company reported no borrowings under its $1.0 billion revolving credit facility or commercial paper program and said it complied with debt covenants.
Material changes versus FY2016
- International and companion-animal businesses drove the strongest reported growth; the top four products contributed approximately 25% of revenue, and the top ten product lines 39%.
- Consolidated cost of sales rose 7%, but fell to 33% of revenue from 34%; SG&A fell 2% and declined to 25% of revenue from 28%. R&D expense increased 2% to $382 million.
- Reported net income grew more slowly than pretax income, as the effective tax rate rose to 43.5% from 33.3%. The increase primarily reflected a provisional $212 million net tax expense tied to the Tax Cuts and Jobs Act, including deemed repatriation tax, partly offset by deferred-tax remeasurement.
- Share repurchases totaled approximately $500 million in 2017; about $1.0 billion remained under the authorization at year-end. Dividends declared were $0.441 per share, up from $0.390.
- Fourth-quarter revenue was $1.460 billion and net income attributable to Zoetis was $81 million, versus $1.277 billion and $154 million, respectively, in Q4 2016. Q4 2017 diluted EPS was $0.16; the quarter included the provisional Tax Act charge.
Outlook, commentary, risks and unusual items
- Management described cash on hand, operating cash flow and available financing as sufficient for foreseeable needs, while noting that economic conditions could affect liquidity. The supplied filing text refers to 2018 financial guidance but does not provide clear numerical guidance values.
- Management’s growth priorities include new products and product lifecycle innovation, emerging markets, customer relationships, manufacturing efficiency and complementary businesses. The operational-efficiency program was substantially complete; approximately 2,600 positions had been eliminated, with about 40 additional planned reductions and some divestiture-related reductions expected to continue.
- Animal-antibacterial regulation and changing consumer preferences are material risks: livestock antibacterials generated about $1.2 billion of revenue. The company reported U.S. feed-additive impacts from the Veterinary Feed Directive.
- Other material risks include product safety or supply interruptions, competition and generic entry, patent expirations, customer consolidation, animal-disease outbreaks, weather and resource constraints, foreign exchange, international regulatory and political exposure, and cybersecurity. Draxxin patent protection was scheduled to expire across key markets beginning in 2018–2019; the filing also describes relevant patent expirations for Revolution and ceftiofur products.
- The Tax Act accounting was provisional and subject to reassessment; approximately $4.5 billion of undistributed non-U.S. earnings was reported. The company also had $161 million of net liabilities associated with uncertain tax positions, excluding interest.
- Legal matters included approximately 266 PregSure-related claims, of which about 168 had been settled for amounts management considered immaterial. Zoetis prevailed on the lascadoil-related claims at the trial court level, but plaintiffs sought an interlocutory appeal. Management considered a material adverse effect from proceedings remote overall, but could not estimate reasonably possible losses above accruals.
- The 2017 financial statements received an unqualified audit opinion, and the auditor expressed an unqualified opinion on the effectiveness of internal control over financial reporting.
Important facts for investors to verify
- Reconcile reported and adjusted earnings, especially the provisional Tax Act charge and the non-GAAP exclusions.
- Track 2018 revenue and margin performance by segment, species and product, including Apoquel and other dermatology products.
- Assess the impact of antibacterial-use restrictions, generic competition and key product patent expirations on sales and margins.
- Review debt maturities, interest costs, covenant headroom, cash availability and the use of cash for repurchases and dividends.
- Monitor the resolution of tax audits and the final measurement of Tax Act effects, as well as material litigation and environmental contingencies.